<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20170201032346N4</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-11-28</date_registration>
      <primary_sponsor>Ramsar Campus, Mazandaran University of Medical Sciences</primary_sponsor>
      <public_title>The effects of nebulized salbutamol on transient tachypnea of neonates treatment.</public_title>
      <acronym></acronym>
      <scientific_title>The effects of nebulized salbutamol on Transient Tachypnea of Neonates (TTN) treatment in Neonatal Intensive Care Unit (NICU) of Rajaei hospital of Tonekabon.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2016-12-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>88</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/25232</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: participant are randomized with Distance randomization method. two groups of 44 patients are assigned to treatment or placebo group. each patient is assigned to a unique code provided by Distance randomization service from www.sealedenvelope.com, Blinding description: Placebo are provided by the company producing the product. in terms of appearance drug and placebo are identical. Caregivers prescribe the drug. The research technician is assigned to lead two arms of study based on patient's assigned group. Caregivers, investigators and data analyser are blinded to the study groups.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Transient tachypnea of neonates.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Inhalational 15mg/kg salbutamol  (Ventolin Respiratory Solution, salbutamol sulfate 5 mg/mL) in 2 mL of 0.9 saline in a single dose is administered by nebulizer. Intervention 2: Control group: 2 cc of 0.9% saline is used in a single dose by nebulizer.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
all collected deidentified data for primary and secondary outcome measures are going to be shared

When:
after publishing the study, data are going to be available

To whom:
data are going to be available to all researchers and clinician irrespective to their employment sector

Conditions:
permission are granted upon request for secondary and meta-analysis

Where to obtain:
requests are gathered through principle researcher's e-mail address

How to obtain:
upon verification of request and reason data are given in three month.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Firouzi Hossein</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.20 ,Taleghani Ave., Ramsar.</address>
        <city>Ramsar</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4691786953</zip>
        <telephone>+1 155230181</telephone>
        <email>firoozihosein@mazums.ac.ir</email>
        <affiliation>Ramsar Campus, Mazandaran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Firouzi Hossein</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.20 ,Taleghani Ave., Ramsar.</address>
        <city>Ramsar</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4691786953</zip>
        <telephone>+1 155230181</telephone>
        <email>firoozihosein@mazums.ac.ir</email>
        <affiliation>Ramsar Campus, Mazandaran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Diagnosis of TTN before 6 hour of birth according to Rawling and Smith criteria.</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>3 days</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Diagnosis of respiratory distress syndrome
Presence of end-organ dysfunction
Sepsis Diagnosis</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>P22.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Transient tachypnea of newborn</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Inhalational 15mg/kg salbutamol  (Ventolin Respiratory Solution, salbutamol sulfate 5 mg/mL) in 2 mL of 0.9 saline in a single dose is administered by nebulizer.</i_keyword>
      <i_keyword>Control group: 2 cc of 0.9% saline is used in a single dose by nebulizer.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>TTN score. Timepoint: 20 minutes and 6 hours after treatment. Method of measurement: According to clinical severity criteria of transient tachypnea of neonates, disease is scored from 0 to 13. Higher score indicate more severe disease. The criteria includes: Expiratory grunting: None=0, Intermittent=1, Continuous=2. Supraclavicular Retraction: None=0,  Mild=1, Moderate=2, Severe=3. Subcostal Retraction: None=0, Mild=1, Moderate=2, Severe=3. Cyanosis: None=0, Acral=1, Central=2. Nasal Flaring: None=0, Mild=1, Moderate=2, Severe=3.</prim_outcome>
      <prim_outcome>Heart rate. Timepoint: 20 minutes and 6 hours after treatment. Method of measurement: Cardiac Monitoring. Beats per minutes.</prim_outcome>
      <prim_outcome>Respiratory rate. Timepoint: 20 minutes and 6 hours after treatment. Method of measurement: Cardiac Monitoring. cycle per minutes.</prim_outcome>
      <prim_outcome>O2 Saturation. Timepoint: 20 minutes and 6 hours after treatment. Method of measurement: Pulseoximeter, Percentage.</prim_outcome>
      <prim_outcome>Body temperature. Timepoint: 20 minutes and 6 hours after treatment. Method of measurement: Thermometer. degree of Celsius.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Ramsar Campus, Mazandaran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-11-25</approval_date>
        <contact_name>Ethics committee of Mazandaran University of Medical Sciences</contact_name>
        <contact_address>Mazandaran University of Medical Sciences, Vice Chancellor of Research, Moalem st, Moalem sq, Sari, Mazandaran, Iran. Sari Mazandaran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
